BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Up 81.0% in January

BrainsWay Ltd. (NASDAQ:BWAY) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 49,600 shares, an increase of 81.0% from the December 31st total of 27,400 shares. Based on an average daily trading volume, of 76,700 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of BrainsWay in a research note on Monday, December 23rd.

BrainsWay Trading Down 1.0 %

BrainsWay stock opened at $10.51 on Friday. The firm has a market capitalization of $197.80 million, a P/E ratio of 105.11 and a beta of 1.23. The business has a 50-day moving average of $9.87 and a 200-day moving average of $8.97. BrainsWay has a 1 year low of $4.61 and a 1 year high of $11.25.

BrainsWay (NASDAQ:BWAY) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The firm had revenue of $10.50 million during the quarter, compared to analysts’ expectations of $10.07 million. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. During the same quarter in the previous year, the company earned ($0.01) earnings per share. Research analysts anticipate that BrainsWay will post 0.08 EPS for the current fiscal year.

Institutional Trading of BrainsWay

Several hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its stake in BrainsWay by 316.3% in the third quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock valued at $136,000 after acquiring an additional 11,221 shares during the period. Rhumbline Advisers grew its position in shares of BrainsWay by 10.8% in the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock valued at $207,000 after purchasing an additional 2,144 shares during the period. Finally, Good Life Advisors LLC increased its stake in BrainsWay by 65.5% during the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock worth $516,000 after purchasing an additional 22,080 shares in the last quarter. Institutional investors and hedge funds own 30.11% of the company’s stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.